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Molecular genetic analysis using 
targeted NGS analysis of 677 
individuals with retinal dystrophy
Cathrine Jespersgaard1, Mingyan Fang2,3,4, Mette Bertelsen1,5, Xiao Dang2,3, Hanne Jensen5, 
Yulan Chen2,3, Niels Bech5, Lanlan Dai2,3, thomas Rosenberg  5, Jianguo Zhang2,3, 
Lisbeth Birk Møller  1, Zeynep tümer1,6, Karen Brøndum-Nielsen1 & Karen Grønskov  1
Inherited retinal diseases (IRDs) are a common cause of visual impairment. IRD covers a set of 
genetically highly heterogeneous disorders with more than 150 genes associated with one or more 
clinical forms of IRD. Molecular genetic diagnosis has become increasingly important especially due to 
expanding number of gene therapy strategies under development. Next generation sequencing (NGs) 
of gene panels has proven a valuable diagnostic tool in IRD. We present the molecular findings of 677 
individuals, residing in Denmark, with IRD and report 806 variants of which 187 are novel. We found 
that deletions and duplications spanning one or more exons can explain 3% of the cases, and thus copy 
number variation (CNV) analysis is important in molecular genetic diagnostics of IRD. seven percent 
of the individuals have variants classified as pathogenic or likely-pathogenic in more than one gene. 
possible Danish founder variants in EYS and RP1 are reported. A significant number of variants were 
classified as variants with unknown significance; reporting of these will hopefully contribute to the 
elucidation of the actual clinical consequence making the classification less troublesome in the future. In 
conclusion, this study underlines the relevance of performing targeted sequencing of IRD including CNV 
analysis as well as the importance of interaction with clinical diagnoses.
The introduction of next generation sequencing (NGS) has improved molecular genetic diagnosis of genetically 
heterogeneous conditions substantially. This is also true for inherited retinal diseases (IRDs) which are associated 
with sequence variations in more than 150 genes (https://sph.uth.edu/retnet/). IRDs encompass a heterogeneous 
group of retinal disorders with degeneration of photoreceptors, and are considered one of the leading causes of 
visual impairment in children and young individuals1. Retinitis pigmentosa (RP) is the most frequent clinical 
diagnosis of the IRD specific diagnostic subgroups with a worldwide prevalence of 1:40002. Diagnoses include 
both syndromic and non-syndromic conditions. IRD can be inherited as autosomal recessive (AR), autosomal 
dominant (AD), X-linked (XL) and mitochondrial traits; furthermore, digenic inheritance has been reported in 
rare cases3.
A genetic diagnosis is not only important to improve the genetic counselling of the families and for prognostic 
reasons but also for identifying patients that might benefit from new candidate treatments such as gene therapy, 
where promising results are being reported in numerous clinical trials worldwide4.
In this study, we present genetic investigation of a cohort of 677 individuals residing in Denmark and clinically 
diagnosed or suspected with IRD. Coding regions together with 20 bp flanking intronic sequence and untrans-
lated regions (UTRs) of 125 genes previously shown to be associated with IRD, were analyzed using panel-based 
NGS.
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We report all variants that could be potentially disease causing; it is noteworthy that the number of rare 
variants per individual requires meticulous scrutiny combining several tools; and a close collaboration between 
clinical and laboratory medicine is mandatory.
Results
patient characteristics. Patients clinically suspected of having a retinal dystrophy were selected for the tar-
geted analysis based on evaluation of available clinical records (clinical diagnosis, clinical history, fundus changes, 
OCT imaging, ERG, visual acuity, visual fields, family history). A total of 677 individuals were investigated by a 
targeted NGS panel consisting of 125 genes. Samples have been collected to a clinical biobank over many years. 
The clinical diagnoses were divided into seven groups (Table S1, Fig. 1A). The group “Generalized retinal dys-
trophies” which includes RP and cone-rod dystrophies were by far the most common clinical diagnosis (72%), 
followed by “Macular dystrophy” which includes Stargardt disease (17%)5. The distribution of clinical diagnoses is 
biased due to several previous research projects of specific diagnostic subgroups and diagnostic efforts during the 
years. Individuals with one of following clinical diagnoses: Stargardt disease6, achromatopsia7, Usher syndrome8, 
Bardet-Biedl syndrome9, Best vitelliform macular dystrophy10, choroideremia11, Leber congenital amaurosis12, 
Figure 1. (A) Distribution of 677 individuals in seven groups based on clinical diagnosis. The number in 
brackets refer to the clinical group, and n = number of individuals. (B) Inheritance based on genetic findings 
in 323 individuals with a molecular genetic diagnosis; n = number of individuals. (C) Mutational spectrum of 
variants identified in 677 individuals with IRDs; n = number of individuals.
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XL and AD retinitis pigmentosa13, congenital stationary night blindness14, cone dystrophy and Åland eye dis-
ease15 were included in previous research projects, and are therefore represented by lower numbers than might 
be expected.
NGs panel. The 125 genes in the panel are known to be associated with: retinitis pigmentosa (41%), 
Bardet-Biedl syndrome (14%), cone-rod dystrophy (12%), Leber congenital amaurosis (10%), Usher syndrome 
(7%) and congenital stationary night blindness (3%) (some genes cause more than one eye disorder); Other 
genetic retinal diseases account for a small proportion in the panel (Table S2). 70% of the genes are associated 
with an AR inheritance pattern, 20% with an AD inheritance pattern and 5% with a XL inheritance pattern; fur-
thermore, two genes (PRPH2 and ROM1) have been reported to be involved in digenic inheritance (Table S2).
We obtained on average 1156.22 Mb per individual that mapped to the target region. The mean depth of the 
target regions of all samples was 533X (range from 181X to 1587X) and the average coverage of at least 4X and 
20X was 98.27% and 97.29%, respectively (Table S3).
Variants were filtered based on quality, frequency and function. A total of 7440 rare variants (4030 SNVs 
and 3410 indels) remained with a mean number of 9.24 rare variants per individual (range from 2 to 29). The 
reference sequence is GRCh37/hg19 and the exons are numbered according to reference sequences as listed in 
Table S2.
sequence variations. We report all variants considered to be potentially disease causing, including var-
iants classified as VUS (variant of unknown clinical significance) when it was estimated that they could affect 
the phenotype (Table S4). Variants were classified according to the American College of Medical Genetics and 
Genomics (ACMG) classification. A total of 806 variants, 532 unique variants, are reported; of these 187 were 
novel at the time of manuscript submission. Potential disease causing variants were found in 487 individuals 
while in 190 individuals we found no variants to report (flow of individuals are shown in Fig. 2). Pathogenic or 
likely-pathogenic variants was identified in 429 out of 677 individuals (63%), while 58 individuals out of 677 (9%) 
had either one variant classified as VUS in a gene with AD or XL inheritance, or two variants classified as VUS in 
a gene with AR inheritance. In 323 individuals (48%) a plausible molecular genetic diagnosis could be established 
while in 106 individuals (16%) only one pathogenic or likely-pathogenic variant in an AR gene was identified. 
The study revealed unprecedented complexity in the interpretation of the sequence variants as 7% (47/677) of 
individuals harbored pathogenic or likely-pathogenic variants in more than one gene.
The sequence variations are distributed across 81 genes; 59 genes with AR inheritance (n = 183), 14 genes with 
AD inheritance (n = 77), four with XL inheritance (n = 32) and four genes known with both AR and AD inher-
itance (n = 31) (Fig. 1B). Numbers in brackets indicate the number of individuals. Of the 323 individuals with 
a plausible molecular genetic diagnosis, the most frequently mutated genes were USH2A (n = 42, 6%), ABCA4 
(n = 40, 6%), EYS (n = 29, 4%), RHO (n = 21, 3%), BEST1 (n = 18, 3%), RPGR (n = 17, 2%) and RP1 (n = 15, 2%). 
Variants in these seven genes could explain more than half of the solved cases (182 out of 323, 56%) (Fig. 1C). 
Variants in 22 genes solved only one or two cases each, demonstrating the necessity of a large gene panel for IRD 
analysis. Furthermore, in 47 individuals, sequence variations classified as either pathogenic or likely-pathogenic 
were detected in more than one gene (Table S4).
Figure 2. Flow of individuals. A schematic representation showing the outcome of the 677 individuals with 
IRD participating in the study. *Supplementary Table 4. Indiv: individuals.
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CNV analysis was performed using NGS data, and indications of a deletion or duplication were confirmed 
with another method (MLPA (Multiplex Ligation-dependent Probe Amplification), qPCR (quantitative PCR anal-
ysis) or chromosome microarray). Furthermore, all samples heterozygous for a pathogenic or likely-pathogenic 
sequence variant in ABCA4, USH2A or EYS were analyzed by MLPA to search for deletions and duplications 
which revealed duplications in EYS (case 126) and USH2A (case 297). In total, this strategy detected 17 deletions 
and seven duplications resulting in a molecular genetic diagnosis in 17 cases (Table S5).
Danish disease associated variants and other disease associated founder variants. A novel dis-
ease associated variant, c.232del in EYS, was detected in 11 unrelated individuals. Using the surrounding SNPs in 
EYS we detected a common haplotype spanning 1.9 Mb (chr6:64,431,148-66,415,690, GRCh37/hg19). Likewise, a 
novel disease associated variant, c.2690_2695del in RP1, was detected in five unrelated individuals. Analysis of the 
surrounding SNPs demonstrated a common haplotype spanning 14 kb (chr8:55,528,953-55,543,161, GRCh37/
hg19) (Table S6).
Discussion
Targeted NGS analysis is a valuable method for molecular genetic diagnostics of IRDs as also supported by several 
previous studies16–18. Our detection rate of 48% is relatively low compared to other studies; however, this may be 
biased as our study population was derived from clinical biobank samples that had been extensively investigated 
over the years in several research projects and diagnostics efforts, resulting in many solved cases not included in 
the present study.
A substantial number of individuals were found with only one pathogenic or likely-pathogenic sequence 
variant in a gene with AR inheritance and clinical symptoms that support the genetic diagnosis. This type of 
incomplete genetic diagnosis (missing heritability) is a well-known phenomenon. The missing genetic alterations 
might be found in regulatory regions or deep intron sequences, but also frequent hypomorph variants which are 
filtered out during data analysis or combinations of such in a haplotype could be an explanation of the missing 
heritability. Furthermore, given the high frequency of AR inherited retinal dystrophy, it is of course possible that 
a yet unknown cause is responsible for the eye disorder. Digenic inheritance has also been observed for retinal 
dystrophies, however, we did not observe any obvious signs of this. Whole genome sequencing combined with 
segregation analysis and functional studies could solve some of these cases in future studies.
In 9% of individuals, variants classified as VUS (either one in a gene with AD or XL inheritance, or two in a 
gene with AR inheritance) were identified where the clinical symptoms were supportive. These variants are also 
reported in this study since the classification of variants may change over time, and ideally, variants should be 
classified as either pathogenic (disease associated) or benign; but currently many variants are classified as VUS 
and the only way forward is to report the variants and combine studies.
The most genetically heterogeneous group was the RP group in which causative variations were found in 32 
genes, all of which are known to be associated with RP. The diagnosis Stargardt disease was almost exclusively 
associated with variants in ABCA4. However, we also found one individual with p.(Arg373Cys) missense variant 
in PROM1 which has previously been reported to be associated with Stargardt disease. Notably, we found two 
individuals with truncating variants in CRX. Recently, a nonsense variant in CRX was found in an individual with 
adult onset macular dystrophy19.
CNV analysis revealed a total of 24 deletions and duplications. In some cases their pathogenecity was ques-
tionable, while in others they were plausible explanations. It is obvious that CNV analysis is important in molec-
ular genetic diagnosis of IRD, both shown in the present study and by others in previous studies20.
Several individuals had variants in more than one gene. Six individuals (cases 53, 135, 138, 180, 194 and 202) 
had sequence variations in two genes that potentially both could be the cause of IRD (Table S4). In case 53 (a 
male), a pathogenic change in BEST1 explains the Best vitelliform macular dystrophy phenotype, however, a trun-
cating variant in RPGR would also be expected to be causative. Case 135 was found to be compound heterozygote 
for variants in both EYS and CDH23; he was diagnosed clinically with RP and had a mild hearing impairment. It 
could be speculated that the variants in EYS caused the RP while variants in CDH23 caused the hearing impair-
ment. It is noteworthy though, that analysis restricted to genes known to be associated with Usher syndrome 
based on the clinical symptoms would have revealed only the CDH23 variants while the EYS variants would have 
remained undetected. Case 138 with a clinical diagnosis of congenital stationary night blindness was homozygous 
for likely-pathogenic variants in both GRK1 and TRPM1. Both genes are associated with congenital stationary 
night blindness with AR inheritance. Likewise, case 180 had variants in both PRPF31 and ELOVL4; both genes 
are associated with RP with AD inheritance. Case 194 had deletions in two genes (PRPF31 and IMPDH1); both 
genes show AD inheritance, and both genes are associated with RP. Case 202 had a clinical RP diagnosis and we 
detected a PRPF31 splice variant and two ABCA4 variants. Segregation analysis was unfortunately not possible 
in these cases.
In conclusion, this study shows that targeted NGS is an effective method for establishing a molecular genetic 
diagnosis of IRDs. CNV analysis should be part of the strategy. Using a large gene panel is a prerequisite since 
a similar phenotype can be caused by many genes, and variants can be present in more than one gene, which 
is important knowledge if the result is to be used in treatment purposes and for genetic counseling. We report 
sequence variants both from individuals who received what is considered to be a molecular genetic diagnosis with 
results consequently reported to the clinician, as well as from those receiving a partly molecular genetic diagno-
sis. This information is valuable in the further classification of variants, and in phenotype-genotype correlation 
studies.
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Methods
patients and clinical evaluation. The investigated cohort comprises 677 unrelated individuals residing 
in Denmark with a clinical diagnosis of IRD. Ages of the individuals ranged from 4 to 100 years with a mean age 
of 53.3 years and a median age of 55 years. 493 individuals without a previous molecular genetic diagnosis and 
with a DNA sample in the clinical biobank at Kennedy Center, Rigshospitalet, were identified from the Retinitis 
Pigmentosa Registry and from assessment of clinical records based on diagnosis codes related to any form of 
retinal dystrophy at the Department of Ophthalmology, Rigshospitalet. The Retinitis Pigmentosa Registry is a 
nation-wide register in which all individuals residing in Denmark with a diagnosis of a generalized retinal dys-
trophy born after 1850 has been registered5,21. Furthermore, 184 individuals were enrolled during the study. Most 
participants were of Danish origin. Unfortunately, due to the fact that samples have been collected over many 
years, segregation analysis was in most cases not possible.
The project was approved by The National Committee on Health Research Ethics (Denmark). The project was 
performed according to the Declaration of Helsinki and approved by the Regional Ethics Committee. Written 
informed consent was obtained from all the participants and if under the age of 18 from a parent or legal guard-
ian, before the molecular genetic testing.
Gene selection and target enrichment. We selected 125 genes that were reported to be associ-
ated with inherited retinal disorders according to RetNet database (https://sph.uth.edu/retnet/), OMIM (the 
Online Mendelian Inheritance in Man, http://www.omim.org/) and literature searching (Table S2). The custom 
NimbleGen SeqCap Target Enrichment System (NimbleGen, Madison, WI, USA) was designed to capture and 
enrich all coding exons, 5-/3-UTR regions and 20 bp flanking intronic regions. The size of the target region was 
2.07 Mb and the coverage rate was 95%.
Individuals who were heterozygous for an ABCA4 or USH2A pathogenic or likely-pathogenic variant 
were analyzed for deep intron variants reported to be associated with disease. For investigation of ABCA4 
intronic regions, chr1:94,483,922-94,484,082 and chr1:94,493,000-94,492,973 were amplified using primer 
set ABCA4-V1-3-FH acccactgcttactggcttatcGGGATCATTATGACATCAACCCC and ABCA4-V1-3-RH 
gaggggcaaacaacagatggcCTCCATAGGCTCAGAGATCCC and primer set ABCA4-V4-5-FH acccactgcttact-
ggcttatcACACCATGTAGGTAGGCTTGG and ABCA4-V4-5-RH gaggggcaaacaacagatggcAGGGATCCCAAAA-
GAAGGAC22 respectively, followed by Sanger sequencing. For USH2A, primer set USH2A-intron40-FH 
acccactgcttactggcttatcAGCTTCCTCTCCAGAATCACA and USH2A-intron40-RH gaggggcaaacaacagatggcG-
GTTTTCATCTGGGTCTTGCA were used for PCR amplification, followed by Sanger sequencing. Sequences 
in lower case letters were used as tags for Sanger sequencing. In addition all individuals with a clinical diagnosis 
of Leber congenital amaurosis were investigated for the CEP290 c.2991 + 1655A > G variant using primer set 
CEP290-intron26-FH acccactgcttactggcttatcGGTTCAGGCCGTTCTCCT and CEP290-intron26-RH gagggg-
caaacaacagatggcCACATGGGAGTCACAGGGTA for PCR amplification, followed by Sanger sequencing.
Next-generation sequencing and bioinformatics. Genomic DNA was extracted from peripheral 
blood using standard protocols. The enriched DNA libraries were sequenced using the Illumina HiSeq 2000 
(494 patients) or HiSeq 4000 (184 patients) platforms (Illumina, San Diego, CA, USA). To optimize cost-efficient 
sequencing of the custom target panels, a pilot study was performed, pooling libraries from 1, 2, 5 and 8 sam-
ples. After comparing the sequencing data quality, coverage rate, genotyping concordance, sequencing depth, 
mismatch rate, capture specificity and total detected variants, pooling of five libraries were the optimal strategy.
Raw sequencing image files and base-calling were processed with the Illumine Pipeline and raw paired-end 
low quality reads and adapter sequences were removed using the SOAPnuke software (http://soap.genomics.
org.cn/). The remaining high-quality reads were aligned to the human reference genome (GRCh37/hg19) using 
Burrows–Wheeler Algorithm (BWA) version 0.7.1023, with the MEM algorithm. The SAMtools (version 0.1.19)24 
was used to sort and index SAM/BAM files and the Picard (version 1.117, http://broadinstitute.github.io/picard/) 
was used to mark PCR-duplicates. Local realignment and base recalibration were performed using GATK (ver-
sion 3.3-0)25 and single nucleotide variants (SNVs) and insertions/deletions (InDels) were called with GATK 
HaplotypeCaller.
All identified variants were annotated using Ensembl’s VEP (Variant Effect Predictor)26 and variants were 
prioritized based on the following criteria: (1) variants not present in BGI (Beijing Genome Institute) in-house 
databases and with a minor allele frequency less than 1% using three public variant databases, including 1000 
Genomes Project (KG, http://www.1000genomes.org/), Exome Variant Server (ESP, http://evs.gs.washington.
edu/EVS/) and Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org/); there are known disease 
associated variants causing IRD which have a frequency above 1%, the data were screened for these separately; (2) 
kept all non-synonymous, small indels, frameshift, nonsense, or affect canonical splice-site donor/acceptor sites 
variants. Variants were verified by Sanger sequencing prior to return of results to the clinician.
Interpretation and classification of variants. Sequence variations were classified into five categories: 
pathogenic (class 5), likely-pathogenic (class 4), VUS (class 3), likely benign (class 2) and benign (class 1), accord-
ing to the ACMG guidelines27. Alamut Visual (Interactive Biosoftware, Rouen, France) was used to evaluate 
missense and splice variants. Alamut Visual includes the in silico tools Align GVGD28,29, SIFT30, MutationTaster31 
and PolyPhen232 for missense variants and SpliceSiteFinder-like33,34, MaxEntScan35, GeneSplicer36, NNSPLICE37 
and Human Splicing Finder38 for splice variants.
Deletion and duplication analysis. For targeted NGS samples, copy number analysis was performed 
either using the R software package ExomeDepth (v1.0.7)39 (494 samples) or using the VarSeq Copy number 
variation (CNV) software (184 samples) (Golden Helix, Montana, USA). The ExomeDepth uses read depth data 
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to call CNVs. For each tested individual, the ExomeDepth algorithm builds the most appropriate reference set 
from the BAM files of a group of samples and ranks the CNV calls by their confidence level. The Varseq software 
generates a set of matched reference controls and the sample is compared to this set. A ratio and z-score is com-
puted for each target region defined in the BED file. The z-scores measure the number of standard deviations that 
a sample’s coverage is from the mean coverage of the reference set. CNVs were validated either by MLPA, qPCR 
or chromosome microarray. MLPA was performed using kits P151 and P152 (ABCA4), P361 and P362 (USH2A), 
P328 (EYS) and P235 (PRPF31), following the manufacturer’s instructions (MRC-Holland, Amsterdam, the 
Netherlands). If no MLPA kit was available we performed qPCR using SYBR Power Green (Applied Biosystems, 
Foster City, CA, USA), 50 ng DNA and 12,5 pmol of each primer. Three primer sets were used to verify the 
aberrations and minimum two normal controls were included in the analysis. Real time PCR was run on a 7500 
ABI SDS system (Applied Biosystems). Chromosome microarray was carried out using CytoScan HD array 
(Affymetrix, Santa Clara, CA, USA). Data analysis was performed using ChAS software (Affymetrix).
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